Decreased serum hepatocyte growth factor (HGF) in individuals with depression correlates with severity of disease

Biomarker Insights

Volumn 2010, Issue 5, 2010, Pages 63-67

  Russo, A J ^a  

^a Pfeiffer Treatment Center   (United States)

Author keywords

Biomarker; Depression; Hepatocyte growth factor

Indexed keywords

BIOLOGICAL MARKER; SCATTER FACTOR;

ADULT; ANXIETY; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; DEPRESSION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MALE; PROTEIN BLOOD LEVEL;

EID: 77957102795     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s5183     Document Type: Article

References (42)

1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53:849-57.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-105.
3. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305-15.
4. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227-40.
5. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580-92.
6. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-29.
7. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res. 2002;53:903-6.
8. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19:1097-102.
9. Penninx B, Guralnik J, Pahor M, et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst. 1998;90:1888-93.
10. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry. 2003;54:283-94.
11. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54:269-82.
12. Larson SL, Owens PL, Ford D, Eaton W. Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke. 2001;32:1979-83.
13. Nakamura T, et al. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 1986;83:6489.
14. Nakamura T, et al. Partial Purification and Characterization in hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122:1450.
15. Sasaki M, et al. Identification of mouse mammary fibroblast-derived mammary growth factor as hepatocyte growth factor. Biochem Biophys Res Commun. 1994;199:772.
16. Michalopoulos G, et al. Control of Hepatocyte Replication by Two Serum Factors. Cancer Res. 1984;44:4414.
17. Thaler FJ, Michalopoulos G. Hepatopoietin A: Partial Characterization and Trypsin Activation of a Hepatocyte Growth Factor. Cancer Res. 1985;45:2545.
18. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177.
19. Weidner KM, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A. 1991;88: 7001-5.
20. Comoglio PM, Graziani A. In Guidebook to Cytokines and their Receptors, Nicola NA. editor, Oxford University Press, p. 182. 1994.
21. Comoglio PM, Graziani A. In Guidebook to Cytokines and their Receptors, Nicola NA. editor, Oxford University Press, p. 185. 1994.
22. Grant DS, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A. 1993;90:1937-41.
23. Nakamura T, et al. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 1986;83:6489.
24. Nakamura T, et al. Partial Purification and Characterization in hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1994;122:1450.
25. Sasaki M, et al. Identification of mouse mammary fibroblast-derived mammary growth factor as hepatocyte growth factor. Biochem Biophys Res Commun. 1994;199:772.
26. Michalopoulos G, et al. Control of Hepatocyte Replication by Two Serum Factors. Cancer Res. 1994;44:4414.
27. Thaler FJ, Michalopoulos G. Hepatopoietin A: Partial Characterization and Trypsin Activation of a Hepatocyte Growth Factor. Cancer Res. 1985;45:2545.
28. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177.
29. Weidner KM, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A. 1991;88:7001-5.
30. Hamanoue M, et al. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J Neurosci Res. 1996;43(5):554-64.
31. Tsuboi Y, et al. Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease. Acta neurologica scandinavica. 2003;107:81-6.
32. Sun W, et al. Overexpression of HGF Retards Disease Progression and Prolongs Life Span in a Transgenic Mouse Model of ALS. The Journal of Neuroscience. 2002;22(15):6537-48.
33. Koike H, et al. Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's diseaseGene therapy for Parkinson's disease. Gene Therapy. 2006;13:1639-44.
34. Sarandol A, et al. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative- antioxidative systems Human Psychopharmacology: Clinical and Experimental. 2007;22:67-73.
35. Yanik M, et al. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica. 2004;16:200-3.
36. Kalueff A, Nutt D. Role of gaba in anxiety and depression depression and anxiety. 2007;24:495-517.
37. Zhang X, Youhua L. Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. Am J Physiol Renal Physiol. 2003;284:F1216-25.
38. Borawski J, et al. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients Renal failure 2002; 24:825-37.
39. Bae M, et al. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Experimental Neurology. 2010;221:129-35.
40. Russo AJ, et al. Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with Severe Gastrointestinal Disease Biomarker Insights 2009;2:181-90.
41. Kahl KG, Bens S, Ziegler K, et al. Psychoneuroendocrinology. 2009;34(3): 353-7.
42. Wakatsuki M, Akiyoshi J, Ichioka S, et al. Neuropeptides. 2007;41(6): 477-83.